Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis

Journal of Neuroimmunology

Volumn 80, Issue 1-2, 1997, Pages 76-86

  Sarchielli, Paola ^a   Orlacchio, Antonio ^a   Vicinanza, Federico ^a   Pelliccioli, Gianpiero ^b   Tognoloni, Marinella ^a   Saccardi, Carla ^a   Gallai, Virgilio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MYELIN; NITRIC OXIDE; STEROID; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ADULT; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CLINICAL ARTICLE; CYTOKINE RELEASE; CYTOTOXICITY; DEMYELINATING DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MACROPHAGE; MICROGLIA; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PRIORITY JOURNAL; RELAPSE;

ADULT; CYTOKINES; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LYMPHOCYTES; MALE; MONOCYTES; MULTIPLE SCLEROSIS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITES; RECURRENCE; RNA, MESSENGER;

EID: 0031441476     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00136-7     Document Type: Article

References (51)

1. Albina J.E. On the expression of nitric oxide synthase by human macrophages. Why no NO? J. Leukocyte Biol. 58(6):1995;643-649.
2. Albina J.E., Cui S., Mateo R.B., Reichner J.S. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J. Immunol. 150(11):1993;5080-5085.
3. Benvenuto R., Paroli M., Buttinelli C., Franco A., Barnaba V., Fieschi C., Balsano F. Tumor necrosis factor-alpha synthesis by cerebrospinal fluid-derived T cell clones from patients with multiple sclerosis. Clin. Exp. Immunol. 104:1991;230-234.
4. Bo L., Dawson T.M., Wesselingh S., Mörk S., Choi S., Kong P.A., Hanley D., Trapp B.D. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann. Neurol. 36(5):1994;778-786.
5. Bogdan C., Vodovotz Y., Nathan C. Macrophage deactivation by interleukin 10. J. Exp. Med. 174(6):1991;1549-1555.
6. Bredt D.S., Snyder S.H. Nitric oxide, A physiological messenger molecule. Ann. Rev. Biochem. 63:1994;175-195.
7. Brosnan C.F., Battistini L., Raine C.S., Dickson D.W., Casadevall A., Lee S.C. Reactive nitrogen intermediates in human neuropathology: An overview. Dev. Neurosci. 16(3-4):1994;152-161.
8. Cannella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37(4):1995;424.
9. Chu S.C., Wu H.P., Banks T.C., Eissa N.T., Moss J. Structural diversity in the 5′-untranslated region of cytokine-stimulated human inducible nitric oxide synthase mRNA. J. Biol. Chem. 270(18):1995;10625-10630.
10. Cross A.H., Misko T.P., Lin R.F., Hickey W.F., Trotter J.L., Tilton R.G. Aminoguanidine, an inhibitor of nitric oxide, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J. Clin. Invest. 93(6):1994;2684-2690.
11. Dawson T.M., Dawson V.L., Snyder S.H. A novel neuronal messenger molecule in the brain: The free radical, nitric oxide. Ann. Neurol. 32(3):1992;297-311.
12. de Vera M.E., Shapiro R.A., Nussler A.K., Mudgett J.S., Simmons R.L., Morris S.M. Jr., Billiar T.R., Geller D.A. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: Initial analysis of the human NOS2 promoter. Proc. Natl. Acad. Sci. USA. 93(3):1996;1054-1059.
13. Ding A., Nathan C.F., Stuer D.J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages, Comparison of activating cytokines and evidence for independent production. J. Immunol. 141(7):1988;2407-2412.
14. Farrell A.J., Blake D.R., Palmer R.M., Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann. Rheum. Dis. 51(11):1992;1219-1222.
15. Forstermann U., Kleinert K. Nitric oxide synthase: Expression and expressional control of the three isoforms. Naunyn-Schmiedeberg's Arch. Pharmacol. 352(4):1995;351-364.
16. Glabinski A., Mirecka M., Pokoca L. Tumor necrosis factor alpha but not lymphotoxin is overproduced by blood mononuclear cells in multiple sclerosis. Acta Neurol. Scand. 91(4):1995;276-279.
17. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite and [15N] nitrate in biological fluid. Anal. Biochem. 126:1982;131.
18. Hauser S.L., Doolittle T.H., Lincoln R., Brown R.H., Dinarello C.A. Cytokine accumulations in CSF of multiple sclerosis patients: Frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology. 40(11):1990;1735-1739.
19. Hofman F.M., van Hanwehr R.I., Dinarello C.A., Mizel S.B., Hinton D., Merrill J.E. Immunoregulatory molecules and IL-2 receptors identified in multiple sclerosis brains. J. Immunol. 136:1986;3239-3245.
20. Ialenti A., Ianaro A., Moncada S., Di Rosa M. Modulation of acute inflammation by endogenous nitric oxide. Eur. J. Pharmacol. 211(2):1992;177-182.
21. Ialenti A., Moncada S., Di Rosa M. Modulation of adjuvant arthritis by endogenous nitric oxide. Br. J. Pharmacol. 110(2):1993;701-706.
22. Isobe K., Nakashima I. Abundant production of nitric oxide from murine macrophages by direct stimulation of tumor cells. Biochem. Biophys. Res. Commun. 192(2):1993;499-504.
23. Kleinert H., Euchenhofer C., Ihrig-Biedert I., Forstermann U. Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine induced activity of transcription factor nuclear factor-kappa B. Mol. Pharmacol. 49(1):1996;15-21.
24. Koprowski H., Zheng Y.M., Katz E.H., Fraser N., Rorke L., Fu Z.F., Hanlon C., Dietzschold B. In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc. Natl. Acad. Sci. USA. 90(7):1993;3024-3027.
25. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 33(11):1983;1444-1452.
26. Lin R.F., Lin T.S., Tilton R.G., Cross A.H. Nitric oxide localized to spinal cords of mice with experimental allergic encephalomyelitis: An electron paramagnetic resonance study. J. Exp. Med. 178(2):1993;643-648.
27. Link J., He B., Navikas V., Palasik W., Fredricson S., Söderström M., Link H. Transforming growth factor-β1 suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of interleukin-10 in multiple sclerosis and myastenia gravis: Enhancement by the soluble products of the encephalitogenic T cells. J. Neuroimmunol. 58(1):1995;21-35.
28. Liu J., Zhao M.L., Brosnan C.F., Lee S.C. Expression of type II nitric oxide synthase in primary human astrocytes and microglia: Role of IL-1β and IL-1 receptor antagonist. J. Immunol. 157(8):1996;3569-3576.
29. MacMicking J.D., Willenborg D.O., Weidemann M.J., Rockett K.A., Cowden W.B. Elevated secretion of reactive nitrogen and oxygen intermediates by inflammatory leukocytes in hyperacute experimental autoimmune encephalomyelitis. J. Exp. Med. 176(1):1992;303-307.
30. Maimone D., Gregory S., Arnanson B.G., Reder A.T. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J. Neuroimmunol. 32(1):1991;67-74.
31. Merrill J.E., Ignarro L.J., Sherman M.P., Melinek J., Lane T.E. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151(4):1993;2131-2141.
32. Middleton S.J., Shorthouse M., Hunter J.O. Increased nitric oxide synthesis in ulcerative colitis. Lancet. 341(8853):1993;465-466.
33. Miller M.J., Sadowska-Krowicka H., Chotinaruemol S., Kakkis J.L., Clark D.A. Amelioration of chronic ileitis by nitric oxide synthase inhibition. J. Pharmacol. Exp. Ther. 264(1):1993;11-16.
34. Misko T.P., Trotter J.L., Cross A.H. Mediation of inflammation encephalitogenic cells: Interferon gamma induction of nitric oxide synthase and cyclooxygenase 2. J. Neuroimmunol. 61(2):1995;195-204.
35. Mokhtarian F., Shi Y., Shirazian D., Morgante L., Miller A., Grob D. Defective production of anti-inflammatory cytokine, TGF-β by T cell lines of patients with active multiple sclerosis. J. Immunol. 152(10):1994;6003-6010.
36. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. New Engl. J. Med. 329(27):1993;2002-2112.
37. Mulligan M.S., Hevel Marletta M.A., Ward P.A. Tissue injury caused by deposition of immune-complexes is L-arginine dependent. Proc. Natl. Acad. Sci. USA. 88(14):1991;6338-6342.
38. Navikas V., Link J., Palasik W., Söderström M., Fredrikson S., Olsson T., Link H. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand. J. Immunol. 41(2):1995;171-178.
39. Okuda Y., Nakatsuji Y., Fujimura H., Esumi H., Ogura T., Yanagihara T., Sakoda S. Expression of the inducible isoform of nitric oxide synthase in the central nervous system of mice correlates with the severity of actively induced experimental allergic encephalomyelitis. J. Neuroimmunol. 62(1):1995;103-112.
40. Perez-Mediavilla L.A., Lopez-Zabalza M.J., Calonge M., Montuenga L., Lopez-Moratalla N., Santiago E. Inducible nitric oxide synthase in human lymphomononuclear cells activated by synthetic peptides derived from extracellular matrix proteins. FEBS Lett. 357(2):1995;121-124.
41. Poser C.M., Paty D., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann. Neurol. 13(2):1983;227-231.
42. Reiling N., Ulmer A.J., Duchrow M., Ernst M., Flad H.D., Hauschildt S. Nitric oxide synthase: mRNA expression of different isoforms in human monocytes/macrophages. Eur. J. Immunol. 24(8):1994;1941-1944.
43. Rieckmann P., Albrect M., Kitze B., Weber T., Tumani H., Broocks A., Lüer W., Poser S. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology. 44(8):1994;1523-1526.
44. Schneemann M., Shoedon G., Hofer S., Blau N., Guerrero L., Schaffner A. Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J. Infect. Dis. 167(6):1993;1358-1363.
45. Sharief M.K., Hentges R. Association between tumor necrosis factor alpha and disease progression in patients with multiple sclerosis. New Engl. J. Med. 325(7):1991;467-472.
46. Snyder S.H. Nitric oxide: First in a new class of neurotransmitters? Science. 257(5069):1992;494-496.
47. Tsukada N., Miyagi K., Matsuda M., Yanagisawa N., Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J. Neurol. Sci. 104(2):1991;230-234.
48. Weiz A., Oguchi S., Cicatiello L., Esumi H. Dual mechanism for the control of inducible-type NO synthase gene expression in macrophages during activation by interferon-γ and bacterial lipopolysaccharide. Transcript. Post-Transcript. Regul. 269(11):1994;8324-8333.
49. Woodroofe M.N., Cuzner M.L. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: Detection by nonradioactive in situ hybridation. Cytokine. 5(6):1993;583-588.
50. Zembala M., Siedlar M., Marcinkiewicz J., Pryjma J. Human monocytes are stimulated for nitric oxide release in vitro by some tumor cells but not by cytokines and lipopolysaccharide. Eur. J. Immunol. 24(2):1994;435-439.
51. Zhang X., Laubach V.E., Alley E.W., Edwards K.A., Sherman P.A., Russel S.W., Murphy W.J. Transcriptional basis of responsiveness of the human inducible nitric oxide synthase gene to lipopolysaccharide/interferon-γ J. Leukocyte Biol. 59(4):1996;575-585.